Key facts
- It has raised $1.5M; the latest was Later Stage VC ($1.5M) in Dec 2025.
- Notable investors include High-Tech Gründerfonds, TUDAG, Technologiegründerfonds Sachsen.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for MDTB Cells
- ·The full record, as it builds
Funding rounds
No funding rounds for MDTB Cells are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MDTB Cells
Developer of cell-based immunomodulatory agents and drugs designed to advance regenerative therapies for severe inflammation-associated and age-related diseases. The company offers mesenchymal stromal cell products produced through patented umbilical cord tissue isolation protocols, enabling clinicians and healthcare providers to deliver cost-effective treatments that reduce inflammation and improve outcomes across diverse patient populations.
- Sector
- Healthcare
- HQ
- Dresden, Germany
- Founded
- 2018
- Employees
- 7
- Website
- mdtbcells.com/
- Ownership
- Privately Held (backing)
MDTB Cells doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MDTB Cells shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MDTB Cells in its N-PORT filings yet. We sweep new filings monthly.